Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026

On November 6, 2026 Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, reported that it will host a virtual event on Monday, November 9 at 8:00 AM ET to discuss topline results from its Phase 2 PIK-201 trial exploring PIKTOR in advanced endometrial cancer. To register, click here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature key opinion leader and PIK-201 principal investigator David Starks, MD, MPH (Gynecologic Oncologist, Avera Cancer Institute), who will join company management to provide clinical perspectives on the unmet need and evolving treatment landscape in advanced endometrial cancer.

A live question-and-answer session will follow the formal presentations.

About PIKTOR

PIKTOR is an investigational, proprietary, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway, also known as the PAM pathway. This multi-node approach is designed to address the signaling feedback reactivation and treatment-emergent resistance mutations that may limit the efficacy of single-node PI3K/AKT/mTOR pathway inhibitors. According to published literature, the PAM pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in oncology.

PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201). PIKTOR is also being evaluated in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027.

(Press release, Faeth Therapeutics, NOV 6, 2026, View Source [SID1234674416])

bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization

On November 6, 2026 bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease and topically delivered therapeutics for skin cancer, today reported financial results and business highlights for the third quarter (Q3) ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q3 2026 Highlights and Recent Events

● CyPath Lung test unit sales increased 100% through Q3 compared to the first nine months of 2025.
● CyPath Lung testing revenue for the first nine months of 2026 increased 79% to approximately $1.1 million, compared to the same period in 2025.
● In July 2026, the Company surpassed the total number of CyPath Lung test reports delivered to physicians during 2025.
● The number of ordering physicians increased by 89% in the third quarter of 2026 compared to the third quarter of 2025, continuing to expand clinical utilization of CyPath Lung. Physicians already ordering CyPath Lung tests increased their volume by 48% year over year.
● The Company expanded its government healthcare distribution network and commercial reach through an agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business and established distributor of medical-surgical and laboratory products and services to government agencies, including the Department of Veterans Affairs (VA).
● The ongoing longitudinal clinical trial designed to evaluate the clinical performance of CyPath Lung continued to advance. As of September 30, 2026, 11 clinical sites were active, including nine VA and military medical centers that had begun patient enrollment. The John P. Murtha Cancer Center Research Program at the Uniformed Services University of the Health Sciences is providing support and funding for the trial.

● In July, the Company published a comprehensive clinical review and white paper authored by Chief Medical Officer Gordon H. Downie, MD, PhD, presenting a practical framework for incorporating CyPath Lung into pulmonology and oncology practices. Dr. Downie presented the framework to physicians in October at the annual meeting of the American College of Chest Physicians (CHEST 2026).
● The Company advanced CyPath Lung for potential use in surveillance of lung cancer survivors as a complement to imaging to monitor patients for cancer recurrence and new primary lung cancers.
● The Company presented positive research results at CHEST 2026 relating to its development of noninvasive tests to characterize lung inflammation and investigate biologic drug targets for asthma and COPD therapies. Further development and validation are underway to determine whether this approach can identify patients who may benefit from specific biologic therapies or support monitoring of lung inflammation over time.
● The Company announced a collaboration with Pictor, Inc., a targeted proteomic platform company, to support development and potential commercialization of bioAffinity Technologies’ next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and COPD.
● The Company continued research into potential topically delivered therapeutics for squamous and basal cell skin cancers. Preliminary research findings have demonstrated that self-delivering, stabilized small interfering RNAs (siRNAs) selectively kill squamous and basal carcinoma cells in vitro while sparing noncancerous cutaneous cells.
● In September, bioAffinity announced the grant of a Hong Kong patent covering CyPath Lung’s proprietary flow cytometry + AI platform for predicting the likelihood of lung cancer by characterizing cell populations in sputum. In October, the Company received a Notice of Allowance from the Japan Patent Office indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer used by the CyPath Lung test.
● The Company raised an aggregate of $8.0 million in gross proceeds through a private placement offering in August 2026 and a registered direct offering and concurrent private placement in October 2026 for working capital and general corporate purposes, including support for the ongoing commercialization of CyPath Lung.

Management Commentary

"Our third-quarter results reflect CyPath Lung’s continued momentum in addressing the critical need for early lung cancer detection, driven by both new physicians ordering the test and increased use by existing customers. We believe this growth reflects increasing physician engagement and recognition of the role CyPath Lung can play in managing care for patients at risk for lung cancer. We are also advancing its potential use in surveillance following curative-intent treatment, where CyPath Lung could complement imaging in monitoring for recurrence and new cancers," said Maria Zannes, President of CEO of bioAffinity Technologies. "Peer-to-peer education and growing clinical experience with the test remain important drivers of adoption, while our longitudinal study is designed to generate robust, real-world data across multiple sites to further evaluate how CyPath Lung may support risk assessment and clinical decision-making. Together, these efforts advance our objective of establishing CyPath Lung as a standard of care for evaluating patients at risk for lung cancer.

"We continue to build the foundation for long-term growth. Beyond lung cancer, we are advancing our platform to take advantage of precision medicine opportunities in asthma and COPD, where sputum-based analysis may help characterize lung inflammation and help physicians better match individual patients to available treatments, including Tezspire, Dupixent and Nucala. The tests we are developing are designed to meet a critical need for precision diagnostics in the multi-billion-dollar asthma and COPD therapeutic markets.

"Our patent portfolio now includes 22 awarded U.S. and foreign patents and 36 pending applications. The recent Hong Kong patent and the Japanese patent allowance, once awarded, are important additions to our patent portfolio. Our distribution agreement with AvMEDICAL is intended to expand our reach into government healthcare markets, including the VA, where the substantial burden of lung cancer underscores the need for more effective ways to evaluate pulmonary nodules and improve patient outcomes.

Ms. Zannes concluded, "Our priorities remain disciplined execution, expanding commercial adoption and advancing our clinical and research programs. We are also pursuing topical therapeutic approaches for squamous and basal cell skin cancers based on promising findings involving the CD320 and LRP2 receptors. We believe our expertise in flow cytometry, automated data analysis and siRNA technology provides a foundation for developing differentiated products across these markets. Together, these programs demonstrate our commitment to translating scientific innovation into meaningful new opportunities for patients and the Company."

Third Quarter 2026 Financial Results

Total revenue for the quarter ended September 30, 2026, was approximately $1.1 million, compared with approximately $1.4 million for the same period in 2025. The decrease is due primarily to a decrease in average reimbursement per CyPath Lung test and a slight decline in total cases completed at Precision Pathology Laboratory Services (PPLS) compared to the same period in 2025, in part due to internal business changes at three PPLS research clients. Multiple accounts previously serviced under these clients have since returned to PPLS. The Company is working to restore additional accounts and improve reimbursement levels.

Net loss for the quarter ended September 30, 2026, was approximately $5.3 million, compared with approximately $5.1 million for the third quarter of 2025. The increase in net loss is primarily due to the increase in loss from operations of approximately $3.5 million from approximately $2.3 million in the prior-year quarter, partially offset by a $1.2 million loss from the change in fair value of warrants, compared with a $2.7 million loss in the prior-year quarter.

Cash and cash equivalents were approximately $2.6 million as of September 30, 2026, compared with approximately $6.4 million at December 31, 2025. Subsequent to quarter-end, the Company completed a financing that generated approximately $4.0 million in gross proceeds.

Operating expenses for the third quarter of 2026 were approximately $4.6 million, compared with approximately $3.7 million in the third quarter of 2025.

● Direct costs and expenses were approximately $1.1 million, compared with $942,000 in the prior-year period. The increase primarily reflected additional personnel to process CyPath Lung commercial tests and tests associated with the longitudinal clinical study.
● Research and development expenses increased 18% year over year to approximately $389,000, primarily due to laboratory supplies and costs associated with relocating laboratory facilities in June 2026.

● Clinical development expenses increased 75% to approximately $251,000, compared with approximately $143,000 in the third quarter of 2025. The increase primarily reflected the initiation of clinical trial sites and patient enrollment in the longitudinal clinical study.
● Selling, general and administrative expenses increased 28% to approximately $2.8 million, compared with approximately $2.2 million in the prior-year period. The increase primarily reflected additional sales and marketing personnel and support services to expand commercialization of CyPath Lung.

About CyPath Lung

CyPath Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath Lung analyzes the lung microenvironment by using advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. The test incorporates a novel fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a published clinical trial of high-risk patients, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings. For more information, visit www.cypathlung.com.

(Press release, BioAffinity Technologies, NOV 6, 2026, View Source [SID1234674436])

Onchilles Pharma Reports First Clinical Data at SITC 2026 That N17350 Could Turn One Tumor into a Personalized Cancer Vaccine

On November 6, 2026 Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cancer therapeutics that harness the ELANE pathway, reported preliminary clinical findings from OP-NEU-101, its Phase 1/2 trial of intratumoral N17350 in patients with advanced solid tumors. Derived from a cancer-killing enzyme present in human neutrophils, N17350 is designed to use the injected tumor as a source of antigens that may help train the immune system to attack cancer elsewhere in the body without the need for tumor sequencing, antigen selection, or custom manufacturing. The findings provide an early clinical test of this approach and will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Many personalized cancer immunotherapies today require sequencing each tumor and manufacturing a product for each patient. N17350 is designed to generate a personalized immune response with one medicine, using the tumor itself as the source," said Court R. Turner, J.D., Co-Founder and CEO of Onchilles Pharma. "If the local and distant activity seen throughout our preclinical work can be reproduced in patients, N17350 could generate a response tailored to each patient’s cancer across many solid tumor types."

N17350 builds on breakthrough research published in Cell showing that neutrophils, among the body’s most abundant immune cells, contain an enzyme that can kill cancer cells while sparing healthy tissue, including immune cells. Onchilles engineered that enzyme into an investigational therapy to work in two stages when N17350 is injected into the tumor: 1) selectively kill cancer cells and 2) release the tumor’s own antigens to train the immune system, helping it find and attack disease elsewhere in the body. By targeting a vulnerability shared across many cancers, N17350 is designed to generate a personalized immune response from each patient’s injected tumor without requiring a custom-made or targeted therapy.

"Many intratumoral therapies, including TLR agonists and oncolytic viruses, have shown promise preclinically but failed to demonstrate broad clinical benefit," said Alain Patrick Algazi, M.D., Professor of Clinical Medicine at the University of California San Francisco (UCSF) and presenting author. "The early data from N17350 suggest it may be meaningfully different, with evidence of systemic immune activation and response beyond the injected lesion. If confirmed, this could represent a genuine advance over prior approaches in this space."

The clearest early evidence of activity came from a patient with Merkel cell carcinoma, a rare and aggressive skin cancer that had continued to progress despite avelumab-based treatments and radiotherapy. N17350 was injected into one of six lesions included in the assessment. At Week 8, the investigator’s RECIST 1.1 assessment found that all five non-injected lesions were no longer detectable. These included one lesion selected for precise measurement on scans and four additional lesions being followed for their presence or absence. FDG-PET imaging showed a 56% to 60% reduction in SUVmax across all lesion groups evaluated, reflecting substantially lower uptake of the radioactive glucose tracer used to measure tumor metabolic activity. An independent radiology review of a separate lesion also found reduced FDG uptake, providing a second assessment consistent with activity beyond the injected tumor.

"Seeing all five non-injected lesions become undetectable after treating a single lesion with N17350 is an encouraging early observation, particularly after this aggressive cancer had progressed on prior immunotherapy," said Professor Matteo Carlino, MBBS, Ph.D., FRACP, medical oncologist at Westmead and Blacktown Hospitals and an investigator on the OP-NEU-101 clinical trial. "If confirmed and repeated, this could show that N17350 can turn one treated tumor into an in situ vaccine and mobilize the immune system against cancer throughout the body."

Across the first dose cohort, three heavily pretreated patients received N17350 at 1 mg/mL and completed the dose-limiting toxicity assessment period with no dose-limiting toxicities, supporting progression to the next dose level. Preliminary pharmacokinetic (PK) analysis detected no active N17350 enzyme in plasma at any sampled time point, and no treatment-emergent anti-drug antibodies were detected, consistent with the preclinical PK data. Initial immune profiling in the Merkel cell carcinoma patient showed a shift toward an effector-dominant, less immunosuppressive immune profile. Together, the pharmacokinetic and immune findings suggest that treatment of one tumor may have triggered an immune response that contributed to the activity in the non-injected lesions, rather than active N17350 reaching those tumors through the bloodstream.

SITC 2026 Presentation Details for N17350

Poster: 544
Title: OP-NEU-101: A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determine the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors
Presenting Author: Alain Patrick Algazi, MD, University of California San Francisco
Date: Saturday, November 7
Presentation Hours: 12:15–1:45 p.m. and 6:40–8:10 p.m. MT
Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4–6
About N17350

N17350 is a first-in-class, clinical-stage engineered therapeutic elastase designed for intratumoral administration. It targets the ELANE pathway, a cancer-selective killing mechanism that exploits altered histone H1 biology, a vulnerability shared across diverse cancers. By inducing immunogenic cancer cell death while largely preserving non-cancer and immune cells, N17350 is designed to deliver two complementary waves of activity: rapid, direct tumor killing and an adaptive immune response with the potential to attack tumors beyond the injection site. In preclinical models, N17350 produced broad, genotype-independent tumor regression, CD8+ T cell-mediated antitumor immunity, activity in non-injected tumors, and immune memory.

About OP-NEU-101

OP-NEU-101 (ClinicalTrials.gov Identifier: NCT07339176) is a Phase 1/2, first-in-human, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of intratumoral N17350 in patients with advanced solid tumors. The study is enrolling in Australia and the United States, with dose escalation and optimization in patients with injectable superficial lesions, followed by planned evaluation in visceral lesions and potential indication-specific expansion cohorts.

(Press release, Onchilles Pharma, NOV 6, 2026, View Source [SID1234674417])

HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer

On November 6, 2026 HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and leading developer in novel multi-functional fusion immunotherapeutics, for the treatment of autoimmune diseases, cancer, and senescence-associated dysplasia, reported the Company’s data update for HCW11-040 was selected as one of the Top 150 Abstracts by the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) ("SITC"), out of 1,200 abstract submissions, for its scientific rigor, novelty, clarity, and potential impact on cancer immunotherapy. The Company will present the data update at the 41st Annual Meeting of SITC (Free SITC Whitepaper), taking place from November 4 – 8, 2026, in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Poster (Abstract #394), entitled, "A tetravalent, pembrolizumab-based fusion immunotherapeutic protein targeting exhausted T cells for expansion and activation," will be presented during the Poster Session at the Poster Hall from 10 a.m.–2 p.m. MT and 6 – 8:10 p.m. MT, on Saturday, November 7.

HCW11-040 is a novel, first-in-class, fusion immunotherapeutic that is designed to block the checkpoint receptors and engage the costimulatory receptors, analogous to taking the foot off the brake and simultaneously hitting the gas. In preclinical studies, the blocking activity of PD1-PDL1 interaction demonstrated by HCW11-040 was comparable to pembrolizumab, a generic form of Keytruda. HCW11-040 outperformed pembrolizumab in rejuvenating exhausted T cells against human cancer cells. HCW11-050, the mouse homologue of HCW11-040, was also shown to exhibit better anti-solid-tumor activities against cold tumors than immune checkpoint inhibitors in various relevant tumor efficacy preclinical models. It rejuvenated exhausted T cells and promoted T-cell infiltration into tumors to support cold-to-hot tumor conversion. Thus, HCW11-040 represents a novel cancer immunotherapeutic by combining immune checkpoint blockade with potent cytokine-mediated immune activation, enhancing CD8+ T-cell migration to tumors, and reducing immunosuppression in the tumor microenvironment.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and the company is not affiliated with HCWB.

(Press release, HCW Biologics, NOV 6, 2026, View Source [SID1234674402])

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

On November 6, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The results were presented in a poster by Thomas U. Marron, MD, PhD, of the Tisch Cancer Center at Mount Sinai, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For patients with MSS mCRC whose cancer has progressed despite multiple treatments, treatment options remain limited, even among patients without active liver metastases. Historical studies of available later-line treatment regimens have reported median overall survival of approximately 10–14 months in relevant populations.1,2 Because survival beyond 18 months remains uncommon in this setting, the analysis defined long-term survivors as patients who lived at least 18 months after starting BOT+BAL.

The new SITC (Free SITC Whitepaper) analysis builds on previously reported results from the full 123-patient cohort, which demonstrated median overall survival of 21.2 months and a 33% estimated three-year survival rate, as presented at ESMO (Free ESMO Whitepaper) GI 2026 and published in Clinical Cancer Research. The current post-hoc analysis takes a closer look at the patients who achieved long-term survival, examining their clinical characteristics, the durability of their responses and factors that may help explain their outcomes.

The analysis found that 51% (63/123) of patients survived at least 18 months after starting BOT+BAL, including patients who had received prior immunotherapy and undergone several rounds of different treatment. Among the 63 long-term survivors, median overall survival had not been reached and an estimated 59% were alive at three years.

"For patients with metastatic MSS colorectal cancer without active liver metastases who have exhausted multiple therapies, living another year and a half or more is rare," said Thomas U. Marron, MD, PhD, of the Tisch Cancer Center at Mount Sinai and presenting author of the study. "What is particularly interesting is that the long-term survivors did not fit a single favorable clinical profile. Durable benefit was seen even in patients previously treated with immunotherapy, and a subset remains alive without any further cancer treatment. These findings suggest the potential to meaningfully change the course of disease and provide a compelling rationale for evaluating this approach earlier in treatment."

Clinical Characteristics and Outcomes of Long-Term Survivors

This post hoc analysis compared patients who survived at least 18 months after initiating BOT+BAL (n=63) with those who survived less than 18 months (n=60).

Broad patient characteristics: The two groups were generally similar across the characteristics examined including performance status, previous immunotherapy treatment, metastatic disease characteristics and several prognostic biomarkers.
Durable responses: Among long-term survivors, 35% (22/63) had a confirmed tumor response, including three complete responses in which tumors disappeared. Median duration of response was not reached, with responses lasting at least 37.4 months and 10 ongoing at the time of reporting. Patients in both the full cohort and long-term survivor group received a median of two BOT doses.
Time off treatment: Approximately 24% (15/63), or one in four long-term survivors, were alive and off all anticancer treatment at time of last follow-up. Of these patients, 13 had achieved tumor responses with BOT+BAL.
Prior treatment exposure: Long-term survivors were less likely to have received three or more prior lines of treatment, 56% (35/63) compared with 78% (47/60) of shorter-term survivors.
Safety Findings

No treatment-related deaths were observed. Immune-mediated adverse events occurred more frequently among long-term survivors than in the overall cohort. Immune-mediated diarrhea or colitis was the most frequently reported immune-mediated adverse event. Among long-term survivors who developed it, 97% (33/34) experienced resolution, with a median time to resolution of 13 days. Management included early corticosteroids and TNFα-directed therapy, when appropriate.

"The significance of these data extends beyond the survival milestone itself," said Steven J. O’Day, MD, Chief Medical Officer of Agenus. "Deep responses and durable disease control in heavily pretreated, immunologically cold tumors reinforce the potential of BOT’s differentiated Fc-enhanced immune-priming approach. The association between fewer prior therapies and long-term survival strengthens the rationale for evaluating BOT+BAL earlier in the course of disease. This is central to our Phase 3 ROBBIN strategy, which is designed to evaluate a short course of BOT+BAL before surgery in high-risk MSS colon cancer, with the goal of reducing recurrence, de-escalating the need for chemotherapy and increasing the potential for cure."

The full poster will be available at www.agenusbio.com/publications.

SITC 2026 Presentation Details

Title: Clinical Features of Long-Term Survivors Treated with Next-Generation Anti–CTLA-4 (Botensilimab) Plus Anti–PD-1 (Balstilimab) in Refractory Microsatellite-Stable Metastatic Colorectal Cancer

Presenter: Thomas U. Marron, MD, PhD; Tisch Cancer Center at Mount Sinai, New York, NY

Date: Saturday, November 7, 2026

Time: 10:00 a.m.–2:00 p.m. and 6:00–8:10 p.m. MST | 12:00–4:00 p.m. and 8:00–10:10 p.m. EST

Location: North Building, Lower Level, Exhibition Halls 4–5–6, Phoenix, Arizona

Poster Number: 472

BOT and BAL are investigational outside Armenia and are not approved by the U.S. Food and Drug Administration.

About the C-800-01 Study (NCT03860272)

C-800-01 (NCT03860272) is an ongoing, multicenter Phase 1b clinical trial evaluating botensilimab in combination with balstilimab across advanced solid tumors. The trial enrolled over 400 patients with refractory disease and included tumor types with limited or no responsiveness to prior checkpoint inhibitors. Endpoints included objective response rate (ORR), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).

The data presented at SITC (Free SITC Whitepaper) 2026 are from the MSS mCRC cohort, which included 123 patients without active liver metastases who received BOT 1 or 2 mg/kg every six weeks with BAL 3 mg/kg every two weeks. The primary endpoint was safety and tolerability. The present analysis retrospectively defined long-term survivors as those living at least 18 months from treatment start. Data cutoff was December 13, 2025.

(Press release, Agenus, NOV 6, 2026, View Source [SID1234674418])